Company record · BMY · Pharmaceutical Preparations

Bristol Myers Squibb

We could not establish Bristol Myers Squibb's principal financial officer from its filings: From the 10-K filed 2026-02-11: title "Chief Financial Officer (Principal Financial Officer)" is not a verbatim CFO or principal financial officer title.

The record holds Bristol Myers Squibb's 10-K filed February 11, 2026, where no CFO signature could be established, and no Form 8-K CFO change.

The CFO seat

Computed from the records below: a move filed on or after the 10-K replaces the 10-K's signature.

Status	Not established
Basis	Not established from the 10-K filed February 11, 2026

Seat timeline

Every verified record for this seat, newest first, dated as the filing states it.

2026-02-1110-K signature
CFO signature not established from the annual report
10-K filed February 11, 2026 · sec.gov

Company

Ticker	BMY
SEC CIK	0000014272
Industry (SIC)	Pharmaceutical Preparations (2834)

Same industry on the record

Other companies the roster files under SIC “Pharmaceutical Preparations”.

Cadrenal Therapeutics, Inc.CVKD

Interim CFO: John P. Sharp · effective June 25, 2026

Petros Pharmaceuticals, Inc.PTPI

Departure disclosed · Robert Weinstein · no successor on the record yet

Actinium Pharmaceuticals, Inc.ATNM

CFO: Matt David, M.D. · effective October 14, 2026

Adial Pharmaceuticals, Inc.ADIL

Departure disclosed · Vinay Shah · no successor on the record yet

BeyondSpring Inc.BYSI

CFO: Na Li · effective July 1, 2026

CalciMedica, Inc.CALC

Departure disclosed · Stephen Bardin · no successor on the record yet

Cue Biopharma, Inc.CUE

CFO: James Ahlers · effective July 30, 2026

Emergent BioSolutions Inc.EBS

Change disclosed, effective January 1, 2027 · incoming: Frank Vargo

This record covers what the tracked filings state; it is not a complete history of the company's finance leadership. Spot an error? Send a correction.